Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Race Oncology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Race Executes Global License Agreement with City of Hope to Access FTO IP
Details : Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene may be the most potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 07, 2023
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Race Oncology
Deal Size : Undisclosed
Deal Type : Licensing Agreement